Skip to content

Effect of Gum-Guggulu on Obesity

EVALUATION OF FRESH (NAVEENA) AND OLD (PURANA) GUGGULU W.S.R. TO THEIR ANTI-HYPERLIPIDAEMIC(MEDOHARA) EFFECT

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2011/11/002117
Enrollment
60
Registered
2011-11-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- patients suffering from Hyperlipideamia

Interventions

Intervention1: Gomutra shodhita Puran Guggulu : Gomutra shodhita Puran Guggulu 1 pill of 1 gm twice a day With Luke warm water for 2 months Control Intervention1: Gomutra shodhit naveena Guggulu: Gomu

Sponsors

Gujarat Ayurved University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Classical signs and symptoms of Medoroga Age between 20 to 60 years Elevated levels of Serum Cholesterol more than 200mg per dL Elevated Serum Triglycerides more than150mg per dL Elevated Serum LDL more than 130mg per dL and or Elevated Serum VLDL more than40mg per dL BMI between 25 to 40

Exclusion criteria

Exclusion criteria: Age of patients less than 20 years and more than 60 years Obesity of secondary or associated with hypothyroidism hyper tension Diabetes mellitus cushings syndrome Any concomitant serious disorders of the liver kidneys heart lung and other organs Gravid women and lactating mother Person undergoing treatment for any other serious illness BMI less than 25 and more than 40 will be excluded

Design outcomes

Primary

MeasureTime frame
A special scoring pattern will be designed for assessing improvement in signs and symptoms Laboratory investigations ie serum cholesterol serum triglyceride HDL LDL VLDL etc before and after treatment will also be considered as assessment criteria STATISTICAL TEST Students t test will be applied to test the level of significance of the therapy Timepoint: 2 months

Secondary

MeasureTime frame
exacerbation in signs and symptomsTimepoint: 14 days

Countries

India

Contacts

Public ContactProf PK Prajapati

IPGTRA

prajapati.pradeep1@gmail.com09428315733

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026